Dofetilidum [Inn-Latin]
Brand names,
Dofetilidum [Inn-Latin]
Analogs
Dofetilidum [Inn-Latin]
Brand Names Mixture
Dofetilidum [Inn-Latin]
Chemical_Formula
C19H27N3O5S2
Dofetilidum [Inn-Latin]
RX_link
http://www.rxlist.com/cgi/generic2/dofetilide.htm
Dofetilidum [Inn-Latin]
fda sheet
Dofetilidum [Inn-Latin]
msds (material safety sheet)
Dofetilidum [Inn-Latin]
Synthesis Reference
No information avaliable
Dofetilidum [Inn-Latin]
Molecular Weight
441.567 g/mol
Dofetilidum [Inn-Latin]
Melting Point
No information avaliable
Dofetilidum [Inn-Latin]
H2O Solubility
No information avaliable
Dofetilidum [Inn-Latin]
State
Solid
Dofetilidum [Inn-Latin]
LogP
4.574
Dofetilidum [Inn-Latin]
Dosage Forms
Capsule
Dofetilidum [Inn-Latin]
Indication
For the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm
Dofetilidum [Inn-Latin]
Pharmacology
Dofetilide is an antiarrhythmic drug with Class III (cardiac action potential duration prolonging) properties and is indicated for the maintenance of normal sinus rhythm. Dofetilide increases the monophasic action potential duration in a predictable, concentration-dependent manner, primarily due to delayed repolarization. At concentrations covering several orders of magnitude, Dofetilide blocks only IKr with no relevant block of the other repolarizing potassium currents (e.g., IKs, IK1). At clinically relevant concentrations, Dofetilide has no effect on sodium channels (associated with Class I effect), adrenergic alpha-receptors, or adrenergic beta-receptors.
Dofetilidum [Inn-Latin]
Absorption
>90%
Dofetilidum [Inn-Latin]
side effects and Toxicity
No information avaliable
Dofetilidum [Inn-Latin]
Patient Information
No information avaliable
Dofetilidum [Inn-Latin]
Organisms Affected
Humans and other mammals